首页> 外文期刊>Osteoporosis International >The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis
【24h】

The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis

机译:复方中草药治疗绝经后骨质疏松症的首个多中心随机临床试验

获取原文
获取原文并翻译 | 示例
           

摘要

Summary This multicenter and randomized clinical trial showed that daily oral herbal formula Xian Ling Gu Bao (XLGB) was safe in postmenopausal women over a 1-year treatment. Those patients (n ∼ 50) treated with XLGB at the conventional dose demonstrated a statistically significant increase in dual-energy X-ray absorptiometry (DXA) bone mineral density (BMD) at lumbar spine at 6 months and a numerically increased BMD at 12 months.
机译:总结这项多中心随机临床试验表明,每日口服草药配方仙灵骨宝(XLGB)在绝经后妇女中经过1年的治疗是安全的。常规剂量的XLGB治疗的这些患者(n〜50)在6个月时腰椎的双能X线骨密度仪(DXA)骨矿物质密度(BMD)显着增加,在12个月时BMD数值增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号